Menú
Menú
Menú
Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau.
Nanoligent uses state-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy
Nanoligent’s Groundbreaking Drug Targets CXCR4 to Halt Tumor Growth and Metastasis
Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.
Our technology allows the design of new protein conjugates organized as nanoparticles and capable of targeting specific biological systems. This protein architecture is highly stable upon administration in vivo, allowing not only long-lasting systemic circulation but also site-specific drug delivery. Precision medicine aiming high therapeutic index and low side effects for oncology.
We’re pioneering a new generation of precision nanomedicines: harnessing the power of smaller peptides and self-assembling nanotechnology for safer, more effective treatment against CXCR4+ cancer cells. Our initial drug, tailored for CXCR4+ tumor cells, is poised for personalized, tumor-agnostic approval, addressing patients with CXCR4 receptor overexpression, irrespective of primary tumor site.
The technology we’ve developed holds promise beyond cancer, potentially revolutionizing targeted drug delivery for various human conditions, utilizing different biomarkers.
We’re a team of visionaries and experts committed to changing the future of medicine. Founded in 2017 by distinguished professors Dr. A. Villaverde, Dr. E. Vázquez, Dr. R. Mangues, and entrepreneur Dr. M. Rodríguez, Nanoligent boasts a leadership team with unparalleled expertise in nanobiotechnology and oncology.
As we embark on this journey through the world of scientific publications, we invite you to join us in the pursuit of knowledge and the quest for solutions to some of the most pressing questions in our fields. From groundbreaking research to cutting-edge discoveries, these publications represent a collective effort to expand the frontiers of human knowledge.
So, let us begin this intellectual voyage together, as we delve into the captivating world of scientific exploration and innovation, where each publication is a step towards a brighter and more informed future
We’re pioneering a revolutionary approach to drug design and development through cutting-edge nanobiotechnology. Our innovative platform leverages state-of-the-art protein engineering to create targeted drug therapies with unmatched precision and safety.
Our technology revolves around the design of protein conjugates organized as nanoparticles. These nanoparticles are capable of precisely targeting specific biological systems, ensuring the medication reaches its intended destination with pinpoint accuracy. Unlike traditional therapies, our protein architecture remains highly stable upon administration in the body, resulting in long-lasting systemic circulation and site-specific drug delivery.
This breakthrough approach is the key to precision medicine in oncology, offering a high therapeutic index while minimizing side effects. By employing specific ligands, our medicines selectively target affected cells, delivering the desired cargo with unparalleled accuracy. Moreover, our humanized scaffolds prevent undesired immune responses, further enhancing the safety and efficacy of our treatments.
Our commitment to reducing systemic toxicity while enhancing treatment efficacy has the potential to transform the landscape of cancer therapy. We’re dedicated to developing safer and more effective medicines that improve the lives of patients.
Our technology revolves around the design of protein conjugates organized as nanoparticles. These nanoparticles are capable of precisely targeting specific biological systems, ensuring the medication reaches its intended destination with pinpoint accuracy. Unlike traditional therapies, our protein architecture remains highly stable upon administration in the body, resulting in long-lasting systemic circulation and site-specific drug delivery.
This breakthrough approach is the key to precision medicine in oncology, offering a high therapeutic index while minimizing side effects. By employing specific ligands, our medicines selectively target affected cells, delivering the desired cargo with unparalleled accuracy. Moreover, our humanized scaffolds prevent undesired immune responses, further enhancing the safety and efficacy of our treatments.
Our commitment to reducing systemic toxicity while enhancing treatment efficacy has the potential to transform the landscape of cancer therapy. We’re dedicated to developing safer and more effective medicines that improve the lives of patients.
Imagine a world where cancer treatment is not a one-size-fits-all approach, but a precision science. Nanoligent is leading the charge in developing nanomedicines that revolutionize cancer therapy. Our technology enables us to precisely target and destroy cancer cells while sparing healthy tissue. With a high therapeutic index and minimal side effects, we’re redefining the future of oncology treatments.
In the world of biotechnology, success hinges on the people behind the innovation. Nanoligent boasts a team of visionary leaders and distinguished academics who have dedicated their careers to advancing nanobiotechnology and oncology. Our CEO, Montserrat Cano, provides strategic direction, while our scientific collaborations with top institutions ensure our solutions are rooted in cutting-edge science. With a track record of groundbreaking research, our team is poised to deliver game-changing results.
Cancer remains one of the leading causes of death worldwide, with metastasis and chemotherapy-associated toxicity posing significant challenges. Nanoligent is tackling these issues head-on. Our first drug, NNL-121, is designed to target the CXCR4 receptor found in a range of cancers, offering hope to patients with limited treatment options. By significantly reducing metastasis and minimizing toxicity, we’re addressing critical unmet needs in cancer care.
Investing in Nanoligent isn’t just a bet on innovative science; it’s an opportunity to tap into a vast market. With cancer affecting millions globally, the demand for safer, more effective treatments is insatiable. Moreover, our technology isn’t limited to oncology; it has the potential for applications in various human pathologies. By joining us on this journey, you’re not only supporting groundbreaking science but also positioning yourself in a burgeoning market with immense growth potential.
Invest in Nanoligent today and be part of a transformative revolution in medicine.
Financiado por la Unión Europea – NextGenerationEU. Sin embargo, los puntos de vista y las opiniones expresadas son únicamente los del autor o autores y no reflejan necesariamente los de la Unión Europea o la Comisión Europea. Ni la Unión Europea ni la Comisión Europea pueden ser consideradas responsables de las mismas.